摘要
目的:观察重组人生长激素治疗特发性弱精子症的临床疗效和安全性。方法:采用随机对照实验设计,按WHO的标准诊断为特发性弱精子症40例患者,随机均分为应用组和对照组。在常规治疗下,应用组加用重组人生长激素,每次4U,隔日晚上皮下注射,对照组不加用重组人生长激素;疗程3个月。治疗前后按WHO标准进行精液分析,同时监测性激素、甲状腺功能、肝肾功能、血脂、血糖等指标。最终应用组18例,对照组18例完成本观察。结果:精子存活率应用组提高了(28.60±32.89)%,对照组提高了(8.42±25.87)%,差异有显著性(P<0.01);(a+b)级精子,应用组提高了(18.56±21.19)%,对照组提高了(8.12±24.34)%,差异有显著性(P<0.05);精子密度、精子总量的改善应用组较对照组差异有显著性(P<0.05)。结论:重组人生长激素对特发性弱精子症有辅助治疗效果、安全性高、能提高精子密度和精子总数。
Objective ： To evaluate the clinical efficacy and safety of recombinant human-growth hormone （rhGH） in the treatment of idiopathic asthenospermia. Methods. Forty patients with idiopathic asthenospermia were recruited, randomly divided into an rhGH group and a control group and treated for 3 months. In addition to routine treatment, the rhGH group （n = 18） received rhGH, while the control group （ n = 18 ） underwent the routine treatment only. Before and after the treatment, semen samples were obtained, analyzed and graded according to the WHO laboratory manual, and the serum sexual hormone, thyroxin, liver and kidney function, blood cholesterol and blood glucose level were detected. Results ： Sperm vitality was statistically increased, （ 28.60±32.89 ） % in the rhGH group and （8.42±25.87） % in the control （P〈0.01）, and so was sperm （a ＋b） motility, （18.56±21.19） % in the rhGH group and （ 8.12±24.34 ） % in the control （ P 〈 0.05 ）. Conclusion ： rhGH can be used safely as an effective supplement to medicinal treatment of idiopathic asthenospermia.
出处
《中华男科学杂志》
CAS
CSCD
2007年第3期233-236,共4页
National Journal of Andrology
关键词
特发性弱精子症
男性不育
重组人生长激素
疗效
安全性
idiopathic athenospermia
male infertile
recombinant human-growth hormone
clinical efficacy
security
